Trade Celularity Inc. - CELU CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.053
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02221 %(-$4.44)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.00002 %(-$0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02221 %
  (-$4.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00002 %
  (-$0.00)

Key Stats

• Prev. Close: 1.2284
• Open: 1.2584
• 1-Year Change: -35.9%
• Day's Range: 1.1185 - 1.2584

Trade Celularity Inc. - CELU

About Celularity Inc

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic T cells engineered with a chimeric antigen receptor (CAR) (CAR-T) cells, natural killer (NK) cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, infectious and degenerative diseases. It has four placental-derived allogeneic cell types: T cells, unmodified NK cells, genetically modified NK cells and ASCs, which resulted in four key cell therapeutic programs: CyCART-19, CYNK-001, CYNK-101 and APPL-001, focused on six initial indications. Its CyCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor. CYNK-001 is developing for the treatment of acute myeloid leukemia (AML), a blood cancer, and for glioblastoma multiforme (GBM), a solid tumor cancer, and COVID-19.

Financial summary

BRIEF: For the six months ended 30 June 2021, Celularity Inc revenues was not reported. Net income totaled $30.9M vs. loss of $5.7M. Net income reflects Change in fair value of warrant liabilit increase from $6.6M (expense) to $34.5M (income), Unrealized gain on marketable securities decrease from $42K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.16 to $0.70.